If you live with multiple sclerosis and take melatonin, a 2026 review of 10 studies found no evidence that melatonin reduces relapses, disability progression or new MRI activity, though the certainty of the evidence was low.[1] Small studies hinted at better sleep and less fatigue, but the results were inconsistent. Treat melatonin as a possible sleep aid at most, and talk to your neurologist about dose.
What the review looked at
Melatonin is a hormone that helps set your circadian rhythm, the body’s 24-hour clock.[2] The systematic review gathered 10 studies covering 435 adults with MS. Nine were randomized controlled trials. Doses ranged from 0.5 to 300 mg a day, taken for anywhere from 2 weeks to 14 months. The authors rated the certainty of the evidence as low or very low for every outcome.[1]
What it found
- No evidence of reduced relapses, disability progression or new MRI activity.
- Possible improvements in sleep, fatigue, pain, physical function, mood and some blood markers in small studies, but these were inconsistent and rarely repeated.
- Doses of 0.5 to 25 mg a day were generally well tolerated, though some people stopped taking it and side-effect reporting was incomplete.
- At 300 mg a day, three of four people developed raised liver enzymes. Levels settled after stopping and rose again in one person who restarted.[1]
The bottle may not match the label
Dose is harder to control than it looks. A 2017 lab analysis of 31 melatonin supplements found actual melatonin content ranged from 83% below to 478% above the label, and varied by as much as 465% between batches of the same product. More than 71% missed their label claim by over 10%, and eight contained serotonin.[2]
What to do
- Don’t start, stop or change an MS medication on your own, and don’t count on melatonin to do a disease-modifying drug’s job.
- If you use melatonin for sleep, tell your neurologist and ask what dose makes sense for you. The review’s clearest safety signal came at very high doses.[1]
- Choose a product with independent third-party testing for content, given how far labels can miss.[2]
- If fatigue or poor sleep is wearing you down, raise it as its own problem with your care team rather than assuming it is only the MS.
References
[1] Nabil Y, Ghazou A, Abodabesh S, Mansour A, et al. Melatonin supplementation in multiple sclerosis: a systematic review of clinical, imaging, biomarker, and safety outcomes. Frontiers in Neurology, 2026;17:1889519. Population: 10 independent studies (9 randomized trials, 2 of them crossover, and 1 prospective non-randomized study), 435 adults with MS; doses 0.5-300 mg/day for 2 weeks to 14 months. DOI: https://doi.org/10.3389/fneur.2026.1889519. Finding as used: evidence did not show reductions in relapse activity, disability progression or new MRI activity; small studies suggested possible improvements in sleep, fatigue, pain, physical function, cognition, mood and biomarkers, but results were inconsistent and rarely replicated; 0.5-25 mg/day generally well tolerated, though some participants discontinued and adverse-event reporting was incomplete; at 300 mg/day three of four participants developed hypertransaminasemia, which resolved after withdrawal and recurred on rechallenge in one; certainty of evidence low or very low for every outcome. ↑︎
[2] Erland LA, Saxena PK. Melatonin natural health products and supplements: presence of serotonin and significant variability of melatonin content. Journal of Clinical Sleep Medicine, 2017;13(2):275-281. Population: 31 commercial melatonin supplements analyzed. DOI: https://doi.org/10.5664/jcsm.6462. Finding as used: melatonin mediates circadian rhythms and the sleep cycle; content ranged from -83% to +478% of the label; lot-to-lot variation within a product up to 465%; more than 71% of supplements did not meet the label claim within a 10% margin; serotonin found in eight supplements. ↑︎
Kurt Greiner
Kurt is a digital strategist and IT professional blending emerging technology with practical application to help businesses and individuals streamline their digital presence. His current work focuses on the intersection of intentional living and technological resilience, exploring how individuals can leverage modern tools to navigate the second half of life with purpose.
Leave a Reply